Database
User
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| MEMBRANE POTENTIAL | 21.96±1.49 | human | qHTS-HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 27.48 | human | HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 23.46±5.67 | rat | hepatocytes | MMP assay | decrease | IC50 | 163 | |
| (+-)-4-(2-chlorophenyl)-2-[2-(4-isobutylphenyl)ethyl]-6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine | (+-)-4-(o-Chlorophenyl)-2-(p-isobutylphenethyl)-6,9-dimethyl-6H-thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepine | (+/-)-israpafant |
| 117279-73-9 | 4-(2-Chlorophenyl)-2-(2-(4-isobutylphenyl)ethyl)-6,9-dimethyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine | 4-(2-chlorophenyl)-2-(4-isobutylphenethyl)-6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine |
| 4-(2-chlorophenyl)-2-[2 -(4-isobutylphenyl)ethyl]-6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine | 4-(2-chlorophenyl)-6,9-dimethyl-2-{2-[4-(2-methylpropyl)phenyl]ethyl}-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine | 6H-Thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine, 4-(2-chlorophenyl)-6,9-dimethyl-2-(2-(4-(2-methylpropyl)phenyl)ethyl)- |
| 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine, 4-(2-chlorophenyl)-6,9-dimethyl-2-[2-[4-(2-methylpropyl)phenyl]ethyl]- | 7-(2-chlorophenyl)-9,13-dimethyl-4-{2-[4-(2-methylpropyl)phenyl]ethyl}-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaene; | CAS-117279-73-9 |
| CHEMBL2107428 | DSSTox_CID_312 | DSSTox_GSID_20312 |
| DSSTox_RID_75507 | DTXSID5020312 | GTPL1857 |
| Israpafant | Israpafant [INN] | L000999 |
| LS-185098 | NCGC00183008-01 | Pafnol |
| Q27881903 | RMSWMRJVUJSDGN-UHFFFAOYSA-N | SCHEMBL121588 |
| Tox21_113300 | Y 24180 | Y-24180 |